Skip to content

canopusrecord engine body

field
frontiers
loop
body
docs

vela-science/vela

frontier

cancer-immunotherapy-translation

state

resultsread-only vieweressays

Search Canopus

Jump to a section, signal, campaign, document, primitive, work path, frontier, record index, atlas, constellation, agent, capability, or full-state search.

frontiers / frontier

Cancer immunotherapy translation: which signals generalize, which fail

CC-BY-4.0vfr_416f768132dc85d3

id: vfr_416f768132dc85d3
license: CC-BY-4.0
findings: 15
accepted core: 0
contested: 0

15

findings

0

links

15

sources

15

evidence

0

contested

0.84

avg conf

recordoverview state sources proofenginereviewbodygraph

State

The accepted finding bundles: the reviewed findings that make up this frontier’s state. Each carries its statement, the evidence and confidence behind it, its review state, and its links to other findings.

by type

therapeutic11
observational2
mechanism1
diagnostic1

by review state

unreviewed15

finding bundle anatomy

A finding bundle is the durable object. Source graphs, citation stance, candidate gaps, and agent summaries are derived signals until a review event accepts a reviewable change into this record.

finding statement

Adoptive transfer of T-cell receptor (TCR)-engineered T cells targeting NY-ESO-1 produced durable responses in HLA-A*02:01-restricted patients with synovial sarcoma and metastatic melanoma; afami-cel (FDA approved 2024 for synovial sarcoma) extends precision T-cell therapy beyond CAR-T into MHC-restricted contexts.

therapeutic

evidence

experimental · manual state transition; control details require source inspection

15 atoms

provenance

Robbins et al. J Clin Oncol 2015 (NY-ESO-1 TCR); D'Angelo et al. Nat Med 2024 (afami-cel SPEARHEAD-1)

review state

The example finding is unreviewed. Frontier changes still pass through reviewable changes and accepted events.

15 accepted events

derived signals

Links, candidate gaps, bridges, citation stance, nearby papers, and generated summaries route review. They do not rewrite the record by themselves.

0 linked findings15 reviewable changes

15 findings

proposedunder reviewacceptedcontestedunreviewedretracted

finding bundle
unreviewed
Adoptive transfer of T-cell receptor (TCR)-engineered T cells targeting NY-ESO-1 produced durable responses in HLA-A*02:01-restricted patients with synovial sarcoma and metastatic melanoma; afami-cel (FDA approved 2024 for synovial sarcoma) extends precision T-cell therapy beyond CAR-T into MHC-restricted contexts.
vf_135901a2147dcdb5
therapeutic0.84 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Robbins et al. J Clin Oncol 2015 (NY-ESO-1 TCR); D'Angelo et al. Nat Med 2024 (afami-cel SPEARHEAD-1)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Solid-tumor CAR-T faces consistent failure modes: limited tumor-antigen specificity (most antigens are also expressed on normal tissue), antigen heterogeneity, immunosuppressive microenvironment, and physical exclusion from tumor parenchyma. No solid-tumor CAR-T has produced phase 3 success as of 2024 outside select sarcoma case series.
vf_221614cd5867f903
observational0.83 confidence
evidence unit
meta_analysis · manual state transition
source handle
Brown et al. Nat Rev Cancer 2019 (solid-tumor CAR-T review); Rafiq et al. Nat Rev Clin Oncol 2020
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Anti-LAG-3 + anti-PD-1 combination relatlimab+nivolumab improved progression-free survival in advanced melanoma vs nivolumab alone (RELATIVITY-047); LAG-3 is the third checkpoint after PD-1/PD-L1 and CTLA-4 to demonstrate phase 3 success, validating the multi-checkpoint engagement model.
vf_37e7b64100da1905
therapeutic0.86 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Tawbi et al. NEJM 2022 (RELATIVITY-047)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Adjuvant pembrolizumab after surgery in resected stage III melanoma reduced recurrence vs placebo; this established post-resection adjuvant immunotherapy as standard for high-risk melanoma. Adjuvant immunotherapy for completely resected NSCLC, RCC, and MIBC followed similar trial designs with positive results.
vf_4f3eb1f2b328d55c
therapeutic0.86 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Eggermont et al. NEJM 2018 (KEYNOTE-054 melanoma adjuvant); Felip et al. Lancet 2021 (IMpower010 NSCLC)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Tumor microenvironment immunosuppression mediated by Tregs, MDSCs, M2 macrophages, and inhibitory cytokines (TGF-β, IL-10) limits checkpoint-inhibitor efficacy in solid tumors; depleting or repolarizing these populations is an active therapeutic strategy with multiple agents in phase 2/3 (IL-2 muteins, TGF-β traps, anti-CSF1R).
vf_553c116ba8d9ba0f
mechanism0.78 confidence
evidence unit
meta_analysis · manual state transition
source handle
Chen and Mellman, Immunity 2013; Binnewies et al. Nat Med 2018
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Tumor-infiltrating lymphocyte (TIL) therapy with lifileucel produced durable responses in advanced melanoma post anti-PD-1 progression; FDA approved 2024 for unresectable/metastatic melanoma. The class extends adoptive-cell therapy beyond engineered receptors into autologous polyclonal repertoires.
vf_55818eed146d9467
therapeutic0.85 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Sarnaik et al. J Clin Oncol 2021 (lifileucel C-144-01); FDA approval 2024
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
BCMA-targeted CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel) produces deep responses in heavily pretreated multiple myeloma; the class has extended CAR-T indications beyond CD19 lymphoid malignancies and shown that target choice and CAR design can mitigate antigen-loss escape with co-stimulation engineering.
vf_626fd08e2cc3c3c5
therapeutic0.88 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Munshi et al. NEJM 2021 (ide-cel KarMMa); Berdeja et al. Lancet 2021 (cilta-cel CARTITUDE-1)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Allogeneic CAR-T (off-the-shelf, derived from healthy donor T cells with TCR knockout) is in early clinical development; manufacturing economics favor allogeneic but graft-vs-host risk and host-vs-graft rejection limit persistence vs autologous CAR-T. No allogeneic CAR-T has FDA approval as of 2024.
vf_6e73163465698396
therapeutic0.55 confidence
evidence unit
case_report · manual state transition
source handle
Benjamin et al. Lancet 2020 (UCART19); Melenhorst et al. Nature 2022 (allogeneic safety)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Anti-PD-1 + anti-CTLA-4 combination ipilimumab+nivolumab produces higher response rates and overall survival than monotherapy in melanoma, but at the cost of substantial immune-related adverse events; the combination is now standard for advanced melanoma though sequence-based approaches are being investigated to balance efficacy and toxicity.
vf_7b679475e0384225
therapeutic0.88 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Larkin et al. NEJM 2015 (CheckMate 067); Wolchok et al. NEJM 2017 5-year follow-up
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Microsatellite instability (MSI-H) and mismatch-repair deficiency (dMMR) are validated tissue-agnostic biomarkers for PD-1 inhibitor response; pembrolizumab gained FDA tissue-agnostic approval in 2017 for MSI-H solid tumors, demonstrating that biomarker-driven targeting can succeed across cancer types.
vf_8a8f943dacdf6969
diagnostic0.92 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Le et al. Science 2017; Marabelle et al. J Clin Oncol 2020 (KEYNOTE-158)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Vaccine-based cancer immunotherapy has produced limited efficacy except in specific contexts (sipuleucel-T in prostate cancer, BCG in non-muscle-invasive bladder cancer); the class has been outperformed by checkpoint inhibitors and adoptive cell therapy in most indications. Personalized neoantigen vaccines combined with checkpoint inhibition are an emerging area.
vf_acafb94aab8b312f
therapeutic0.78 confidence
evidence unit
meta_analysis · manual state transition
source handle
Kantoff et al. NEJM 2010 (sipuleucel-T); review: Saxena et al. Nat Rev Cancer 2021
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Anti-PD-1/PD-L1 monotherapy produces durable responses in approximately 20 percent of unselected patients across solid tumors; response rate stratifies by tumor mutational burden, MSI status, and PD-L1 expression but biomarker prediction remains imperfect.
vf_be2fda4ea26a82b3
therapeutic0.86 confidence
evidence unit
meta_analysis · manual state transition
source handle
Larkin et al. NEJM 2015 (CheckMate 067 melanoma); Reck et al. NEJM 2016 (KEYNOTE-024 NSCLC); review: Sharma et al. Cell 2017
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) are the dominant CAR-T toxicities; tocilizumab (anti-IL-6R) and corticosteroids manage CRS without abrogating CAR-T efficacy in approved indications. Standardized grading (ASTCT 2019) enables comparison across trials.
vf_cae37e53a0c04493
observational0.88 confidence
evidence unit
observational · manual state transition
source handle
Lee et al. Biol Blood Marrow Transplant 2019 (ASTCT consensus grading); Maude et al. NEJM 2014
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
T-cell engagers (bispecific antibodies bridging CD3 and tumor antigens like CD20-blinatumomab, BCMA-teclistamab, CD19-glofitamab) provide off-the-shelf alternatives to autologous CAR-T with shorter time-to-treatment and lower CRS severity; their efficacy in MRD-low settings rivals CAR-T in some hematologic malignancies.
vf_dafe9ee40820def8
therapeutic0.86 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Locatelli et al. NEJM 2014 (blinatumomab pediatric ALL); Moreau et al. NEJM 2022 (teclistamab MajesTEC-1)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →
finding bundle
unreviewed
CD19 CAR-T (tisagenlecleucel, axicabtagene ciloleucel) produced complete responses in 70-90 percent of relapsed/refractory pediatric ALL and 40-60 percent of refractory DLBCL in pivotal trials; B-cell aplasia and cytokine release syndrome are the dominant toxicities. The class established CAR-T as a treatment modality for hematologic malignancies.
vf_dfaafa6137fce627
therapeutic0.92 confidence
evidence unit
experimental · manual state transition; control details require source inspection
source handle
Maude et al. NEJM 2018 (tisagenlecleucel pediatric ALL); Neelapu et al. NEJM 2017 (axi-cel DLBCL)
review state
unreviewed
downstream effect
no declared downstream links
inspect finding →